Evidence map›Paper›PMID 38229083›Full record

ArticleBMC public health2024

Community cervical cancer screening and precancer risk in women living with HIV in Jos Nigeria.

F A Magaji, M I Mashor, S A Anzaku, A R Hinjari, N T Cosmas, B V Kwaghe, J M Ali, Elizabeth N Christian, A S Sagay, Ariel Chandler and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

F A MagajiGynecologic-Oncology Division, Department of Obstetrics and Gynecology, University of Jos, Jos, Nigeria. magajif@unijos.edu.ng.
M I MashorDepartment of Histopathology, Jos, Nigeria.
S A AnzakuBingham University Teaching Hospital, Jos, Nigeria.
A R HinjariGynecologic-Oncology Division, Department of Obstetrics and Gynecology, University of Jos, Jos, Nigeria.
N T CosmasGynecologic-Oncology Division, Department of Obstetrics and Gynecology, University of Jos, Jos, Nigeria.
B V KwagheDepartment of Anatomic Pathology and Forensic Medicine, Jos University Teaching Hospital, Jos, Nigeria.
J M AliGynecologic-Oncology Division, Department of Obstetrics and Gynecology, University of Jos, Jos, Nigeria.
Elizabeth N ChristianRobert J. Havey, MD Institute for Global Health, Chicago, IL, USA.
A S SagayGynecologic-Oncology Division, Department of Obstetrics and Gynecology, University of Jos, Jos, Nigeria.
Ariel ChandlerProgram Department Health Analytics, School of Professional Studies, Northwestern University, Chicago, IL, USA.
Imran KhanProgram Department Health Analytics, School of Professional Studies, Northwestern University, Chicago, IL, USA.
Robert L MurphyNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Lifang HouNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
J MusaGynecologic-Oncology Division, Department of Obstetrics and Gynecology, University of Jos, Jos, Nigeria.
University of Jos · NGNorthwestern University · USBingham University · NGCenter for Global Health · USJos University Teaching Hospital · NG

Funding

Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Northwestern/Nigeria Research Training Program in HIV and Malignancies (NN-HAM)D43TW009575 · FIC · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Chad J Achenbach, Jonah Musa · 2014 to 2026
$4.1M
West Africa Self-Sampling HPV Based Cervical Cancer Control Program (WA-SS-HCCP) for WLWHA: Barriers, challenges, and needsU01CA275129 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JANE Louise HOLL, Lifang Hou · 2022 to 2026
$3.2M
Vaginal Microbiome in Cervical Intraepithelial Neoplasia and CancerK43TW011416 · FIC · UNIVERSITY OF JOS · PI MUSA, JONAH · 2019 to 2022
$372k
FIC NIH HHS D43 TW009575FIC NIH HHS D43 TW010540FIC NIH HHS K43 TW011416NCI NIH HHS U01 CA275129
6 · The paper itself

Abstract

backgroundHigh HIV prevalence, and lack of organized screening for the indigent population receiving care and treatment within HIV clinics in low-resource settings increases cervical cancer incidence. We sought to determine predictors of cervical precancer in women living with HIV and receiving cervical cancer screening in Jos, Nigeria.

methodsA cross-sectional study of women living with HIV and receiving care and treatment in adult HIV/AIDS clinics in Jos-Metropolis, Nigeria between June 2020 and April 2023. Ethical approvals were obtained from the ethics committee in Jos, Nigeria and Northwestern University IRB, USA. Informed consent was obtained from eligible participants, and data on socio-demographics, cancer risk factors, and cytology reports were collected. The outcome variables were cervical precancer lesions. The independent variables were prior Pap smear status, socio-demographics, income, educational, and other reproductive health factors. Descriptive statistics was done to obtain means ± sd, frequencies, and percentages for the variables. Univariate and bivariate analyses were done to determine predictors of cervical dysplasia. Analyses were performed using R software.

resultsOf 957 women screened, 570 were living with HIV and 566 women had cytology report and were included in the final analysis. The mean age was 45.08 ± 8.89 years and 81.6% had no prior evidence of Pap test (under-screened). Prevalence of cervical dysplasia was 24% (mild and severe dysplasia were 12.9% and 11.1%, respectively). Age above 45 years (aOR = 3.48, p = 0.009), postmenopausal status (aOR = 7.69, p = 0.000), and women with no history of prior IUCD use (aOR = 5.94, p = 0.0001), were predictors for severe dysplasia. Women who had history of STI (aOR = 0.17, p = 0.000), prior use of IUCD (aOR = 0.32, p = 0.004), prior use of condom (aOR = 2.50, p = 0.003) and had co-morbidities (aOR = 0.46, p = 0.009) were more likely to have had a Pap test in the past.

conclusionsThe majority of indigent women receiving care at HIV clinics had their first Pap test screening, and lack of organized screening among older and post-menopausal women with HIV, puts women at a higher risk of developing severe cervical precancer lesions.

Indexed as

HIV InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsAdultCross-Sectional StudiesEarly Detection of CancerFemaleHumansMass ScreeningMiddle AgedNigeriaPapanicolaou TestVaginal SmearsAdult HIV-clinicCervical precancer and cancerIndigent womenJos-NigeriaPap test

Identifiers

PMID38229083
PMCPMC10790377
OpenAlexW4390918084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.